Bioventus contracts with Aetna Medicare Advantage plans


Pain treatment and surgical solutions leader Bioventus has agreed to contract with Aetna Medicare Advantage plans beginning Jan. 1, 2024. 

Over 3 million Aetna Medicare Advantage plan members nationwide will have access to Durolane, a single-injection hyaluronic acid-based joint-fluid treatment for patients with knee osteoarthritis pain. 

Durolane is now one of two single-injection HA products under contract, according to a Dec. 6 press release from Bioventus. 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Podcast

Featured Whitepapers